The findings provide further support of recommendations in the clinical guidelines to favor one therapy over the other. Patients with chronic obstructive pulmonary disease (COPD) being treated with ...
A Cochrane systematic review has found new moderate-quality evidence that tiotropium + long-acting beta2-agonist/inhaled corticosteroid (LABA/ICS) combination therapy reduces hospital admission for ...
A review of postmarket safety studies by the US Food and Drug Administration (FDA) has found no significant increase in risk for serious asthma-related outcomes when a long-acting β-agonist (LABA) is ...
But these acronyms are some of the building blocks of asthma care and treatment. The challenge? Figuring out what they mean, how they work together, how to use them correctly and which combination is ...
The new long-acting muscarinic antagonist and long-acting beta-agonist (LAMA/LABA) fixed dose combination (FDC) inhaler may be a better option than inhaled corticosteroids (ICS) for long-term use. As ...
About 40% of at-risk patients with COPD did not receive maintenance therapy despite having frequent or severe exacerbations.
The trials did show that ICS/LABA combination medicines were more effective in decreasing asthma attacks (e.g., the need to use oral corticosteroids) compared to ICS alone. This additional information ...
Please provide your email address to receive an email when new articles are posted on . Moving from a low-dose inhaled corticosteroid to a medium-dose inhaled corticosteroid plus a long-acting beta ...
For patients with moderate to severe chronic obstructive pulmonary disease (COPD), treatment options include a long-acting beta-agonist (LABA) alone or a LABA combined with an inhaled corticosteroid ...
When added to ICS, tiotropium and LABAs perform similarly for asthma patients. What is the effect of ICS/LABA controller therapy on asthma in patients with persistent cold airway hyperresponsiveness, ...
Additional data presentations for fluticasone furoate and vilanterol trifenatate support the potential of developmental combination treatment, Relovair, in COPD and asthma LONDON and SOUTH SAN ...
Inhaled corticosteroid–long-acting beta-agonist (ICS-LABA) inhalers are widely prescribed for asthma and chronic obstructive pulmonary disease. ICS-LABAs are largely interchangeable within the class; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results